Primary Hyperoxaluria Clinical Trial
Official title:
A Phase 1/2, Randomised, Placebo-controlled, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of OC5 to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria
The purpose of this study is to determine if Oxalobacter formigenes is effective at lowering urinary oxalate levels in patients with primary hyperoxaluria.
Status | Completed |
Enrollment | 28 |
Est. completion date | January 2015 |
Est. primary completion date | January 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 2 Years and older |
Eligibility |
Inclusion Criteria: - Signed informed consent (as applicable for the age of the subject). - Male or female subjects = 2 years of age (Germany & France) / Male or female subjects = 5 years of age (United Kingdom) - A diagnosis of PH type I, II or III (as determined by standard diagnostic methods). - A mean urinary oxalate excretion of > 1.0 mmol/24h/1.73m2, based on at least three eligible urine collections performed during baseline (weeks 1-4). - Renal function defined as an estimated GFR = 40 ml/min normalised to 1.73m2 body surface area, or a creatinine clearance of = 40 ml/min normalised to 1.73m2 body surface area. - Subjects receiving vitamin B6 must be receiving a stable dose for at least 3 months prior to screening and must not change the dose during the study. Subjects not receiving vitamin B6 at study entry must be willing to refrain from initiating pyridoxine during study participation. Exclusion Criteria: - Inability to collect complete 24-hour urine samples. Each urine collection will be evaluated for completeness based on urine qualitative criteria. - Inability to swallow size 4 capsules twice daily for 8 to 10 weeks. - Subjects that have undergone transplantation (solid organ or bone marrow). - The existence of secondary hyperoxaluria, e.g. hyperoxaluria due to bariatric surgery or chronic gastrointestinal diseases such as cystic fibrosis, chronic inflammatory bowel disease and short-bowel syndrome. - Use of antibiotics to which O. formigenes is sensitive, including chronic use, a history of more than two courses of antibiotic use during the past 6 months, current antibiotic use, or antibiotics use within 14 days of initiating study medication. - Subjects who require immune suppressive therapy. - Current treatment with ascorbic acid preparation. - Pregnancy. - Women of child-bearing potential who are not using adequate contraceptive precautions such as oral, transdermal, injectable, or implanted contraceptives, IUD, complete abstinence, use of a condom by the sexual partner, or sterile sexual partner. - Presence of a medical condition that the Principal Investigator considers likely to make the subject susceptible to adverse effect of study treatment or unable to follow study procedures. - Participation in any study of an investigational product, biologic, device, or other agent within 30 days prior to screening or not willing to forego other forms of investigational treatment during this study. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
France | Hôpital des Enfants, Centre de référence maladies rénales rares du Sud-Ouest (SORARE), CHU de Bordeaux | Bordeaux | |
France | Hôpital Femme Mère Enfant, Lyon - Paediatric Dept | Lyon | |
France | Hôpital Necker-Enfants Malades,Centre de référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA) | Paris | |
France | Hôpital Robert-Debré, Néphrologie Pédiatrique | Paris | Cedex 19 |
Germany | Universitätsklinikum Bonn, Dept of Paediatric Nephrology | Bonn | |
United Kingdom | Birmingham Children's Hospital NHS Foundation Trust - Dept of Nephrology | Birmingham | |
United Kingdom | Great Ormond Street Hospital for Children NHS Trust | London | |
United Kingdom | Royal Free Hospital -UCL Centre for Nephrology | London |
Lead Sponsor | Collaborator |
---|---|
OxThera | FP7-SME-2013 Research for the benefit of SMEs program |
France, Germany, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in urinary oxalate levels from Baseline to week 8 of treatment. | 8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study) | No | |
Secondary | Change in urinary oxalate levels from Baseline to week 8 of treatment in subsets of subjects | Change in urinary oxalate levels from Baseline to week 8 of treatment in subsets of subjects defined by: baseline urinary oxalate level, above and below 1.5 mmol/24h/1.73m2 concomitant vitamin B6 therapy and no vitamin B6 therapy eGFR of =90 mL/min/1.73m2 (normal renal function) and < 90 mL/min/1.73m2 (mild to moderate reduction in renal function) age below 18 and age 18 or above |
8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study) | No |
Secondary | Number of subjects who reach urinary oxalate levels below 0.5, 0.7 and 1.0 mmol/24h/1.73m2 respectively from Baseline to week 8 of treatment. | 8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study) | No | |
Secondary | Change in plasma oxalate levels from Baseline to week 8 of treatment. | 8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study) | No | |
Secondary | Change in urinary oxalate levels from Baseline to week 4 of treatment. | 8 weeks of active treatment (i.e. between Weeks 7 and 10 of the study) | No | |
Secondary | Correlation between change in plasma oxalate levels and change in urinary oxalate levels, from Baseline to week 8 of treatment. | 8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study) | No | |
Secondary | Change in number of O. formigenes in faeces from Baseline to week 8 of treatment. | 8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study) | No | |
Secondary | Adverse events | 8 weeks of active treatment (i.e. between Weeks 7 and 14 of the study) | Yes | |
Secondary | Haematology | Blood samples taken for hematology at weeks 0, 5, 10 and 14. Complete blood count with differential and platelet count evaluated. | 14 weeks (Throughout the study) | Yes |
Secondary | Clinical Chemistry | Blood samples taken for clinical chemistry at weeks 0, 5, 10 and 14. Blood Urea Nitrogen, creatinine, electrolytes (Na+, K+, Mg++, Ca++, HCO3+, Cl), glucose, pH, albumin, alkaline phosphatase, ALT, AST, total bilirubin and total protein evaluated. | 14 weeks (Throughout the study) | Yes |
Secondary | Urinalysis | Urine samples will be taken at weeks 0, 5, 10 and 14 of the study. Protein, glucose and pH evaluated. | 14 weeks (Throughout the study) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT00875823 -
International Registry for Primary Hyperoxaluria
|
N/A | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT02340689 -
Primary Hyperoxaluria Mutation Genotyping/Phenotyping
|
||
Completed |
NCT00638703 -
Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Completed |
NCT03819647 -
Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria
|
Phase 2 | |
Recruiting |
NCT02026388 -
Rare Kidney Stone Consortium Biobank
|
||
Completed |
NCT02000219 -
Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis
|
Phase 2 | |
Recruiting |
NCT05843851 -
Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria
|
N/A | |
Recruiting |
NCT00588562 -
Rare Kidney Stone Consortium Patient Registry
|
||
Completed |
NCT03391804 -
Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
|
Phase 2 | |
Completed |
NCT03116685 -
A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
|
Phase 3 | |
Recruiting |
NCT05107830 -
Phenotyping of Primary Hyperoxaluria
|
||
Active, not recruiting |
NCT04152200 -
A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1
|
Phase 3 | |
Recruiting |
NCT05001269 -
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
|
Phase 2 | |
Completed |
NCT03392896 -
Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria
|
Phase 1 | |
Completed |
NCT01037231 -
Phase 2/3 Oxabact Study
|
Phase 2/Phase 3 | |
Completed |
NCT00589225 -
Primary Hyperoxaluria Mutation Genotyping
|
Phase 1 | |
Completed |
NCT02124395 -
Health-related Quality of Life in Rare Kidney Stone
|
||
Completed |
NCT03350451 -
An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1
|
Phase 2 |